logo
calendar9 Noyabr 2019
view35
Main language:Russian

THE STUDYING OF INFLUENCE NEW ANTINEOPLASTIC PREPARATION К-26 ON SYNTHESIS DNA/RNA AND EXPRESSION OF GENES MDR2 DRUG RESISTANCE AND P53 TUMOR SUPPRESSOR

Field of Science:
pdf

5dc62eb27b9ab.pdf

PDF

"Pharmaceutical Journal"

"Pharmaceutical Journal"

Publish Articlesee more

ARTICLE ANNOTATION

quote
By experiments on studying of influence of preparation К-26 on synthesis DNA and RNA, an expression of MDR2 drug resistance gene and p53 gene it is established, that in tumor cells the preparation suppresses synthesis DNA and RNA than etoposide. Low level of an expression MDR2 gene (within 15 %) in comparison with for the most expression of this gene under influence etoposide is observed. The gene expression р53 considerably increases to 80 % (at etoposide to 55 %), that defnes big ability К-26 to induce tumor apoptosis. Higher level of an expression of gene MDR2 in spleen cages (55 %) under the influence of preparation К-26 that reflects the big sensitivity of a tumor to a new preparation, than a susceptibility of normal body is simultaneously observed. Also in spleen cells the smaller expression of p53 gene caused К-26 in comparison with etoposide is observed, that specifes in less destructive influence К-26 on a spleen. Thereupon, there are strong reasons to study preparation К-26 overcoming resistance for the subsequent influence on a kidney cancer.

AUTHORS

Z.Yenikeeva

M.Tillyashayxov

A.Ibragimov

Tags

# этопозид# etoposide# препарат К-26# синтез ДНК/РНК# экспрессия гена MDR2 и р53# К-26 препарати# ДНК/РНК синтези# MDR2 ва р53 ген экспрессияси# preparation К-26# DNA/RNA synthesis# MDR2 and p53 genes expression

OTHER ARTICLES IN THIS JOURNAL

Rate Article

0
0 ratings
5
4
3
2
1

Article Identifiers

ROI:

https://eroi.uz/11.0035/A1119-0004

DOI:

Not Available

References

1. Еникеева З.М., Ибрагимов А.А. Новый класс цитостатиков со стимуляцией колониеобразующих единиц на селезенке (КОЕс). Ташкент, из-во «Fanvatexnologiya», 173с.

2. Льюин Б.. Гены. Москва, «Мир», 1987, 544с.

3. Маниатис Т., Фрич Э., Сэмбрук Дж. Молекулярное клонирование. Методы генетической инженерии. Москва. «Мир».1984.

4. Руководство по химиотерапии опухолевых звболеваемй. Под ред.Н.И.Переводчиковой. Изд «Практическая медицина, М.,2013г.

5. Самусенко А. В. Механизмы гибели клеток при действии оливомицина и его производных. Автореф., к.м.н., Москва-2009, 19с.

6. Ставровская А. А. Клеточные механизмы множественной лекарственной устойчивости опухолевых клеток / А.А. Ставровская // Биохимия. –2000. – Т. 65. № 1. – С. 112-126.

7. Штиль А.А. Развитие множественной лекарственной устойчивости как срочный ответ клетки на экзогенные воздействия // Биол. Мембраны. –2003. –20(3). – С. 236-243.

8. BaguleyB.C. Multidrug Resistance in Cancer / B.C. Baguley // Methods in Molecular Biology. –2010. – Vol. 596. – P. 1-14.

9. Filipits M. Mechanisms of cancer: multidrug resistance / M. Filipits // Drug Discovery Today: Disease Mechanisms. – 2004. – Vol.1. – №2. – P. 229-234.

10. Fracasso PM, Brady MF, Moore DH, Walker JL, Rose PG, Letvak L, Grogan TM, McGuire WP: Phase II study of paclitaxel and valspodar (PSC 833) in refractory ovarian carcinoma: a gynecologic oncology group study. J Clin Oncol 2001, 19:2975-2982.

11. Goldstein L.J. Expression of a multidrug resistance gene in human cancers / L.J. Goldstein H. Galski, A. Fojo et al. // J.Nat. Cancer Inst. 1989. — Vol. 81. – P. 116-124.

12. Hegewisch-Becker S. The MDR phenotype in hematologic malignancies: prognostic relevance and future perspectives / S. Hegewisch-Becker, D.K. Hossfeld // Ann. Hematol. –1996. –Vol. 72. – P. 105-117.

13. Shah N.P. Mechanisms of resistance to STI571 in Philadelphia chromosome-associated leukemias / N.P.Shah, C.L.Sawyers // Oncogene. – 2003. – Vol. 22. – P. 7389-7395.

14. Shtil A.A. Emergence of multidrug resistance in leukemia cells during chemotherapy: mechanisms and prevention / A.A. Shtil // J.Hematother. Stem Cell Res. –2002. – Vol. 11. – P. 231-241..